Anavex Life Sciences Corporation

AVXL

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
May 13, 2024

Days Left:
-64

calendar

Anavex Life Sciences Corporation Form












Breaking News Stocks does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results. An analyst questioned the Company’s claim noting “there are several key factors that point us to believe the data is provocative, but not yet compelling, given the choice of statistical analyses and other trial design/conduct ‘complexifiers’.” Additionally, a biotech journalist commented on AVXL’s findings stating “[w]hat sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials…Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.”Following this news, AVXL’s stock price fell by $2.47 per share, or approximately 20% to close at $9.58.Further on January 3, 2024, AVXL announced that results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73 in pediatric patients with Rett syndrome failed to show statistical significance towards its primary endpoints. Biotech analysts commented that “the negative study outcome was never in doubt…Anavex is a serial dissembler of clinical trial results.”Following this news, AVXL’s stock price fell by $3.26 per share, or approximately 35%.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Anavex Life Sciences purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Anavex Life Sciences during the relevant time frame, you have until May 13, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker SymbolCompany NameJoin DeadlineJoin
TDOCTeladoc Health, Inc.July 16, 2024Join
VSTSVestis CorporationJuly 16, 2024Join
CMBMCambium Networks CorporationJuly 22, 2024Join
BIIBBiogen Inc.July 22, 2024Join
FSLYFastly, Inc.July 23, 2024Join
ENPHEnphase Energy, Inc.July 29, 2024Join
RIVNRivian Automotive, Inc.July 30, 2024Join
HTZHertz Global Holdings, Inc.July 30, 2024Join
HUMHumana Inc.August 02, 2024Join
MRNSMarinus Pharmaceuticals, Inc.August 05, 2024Join
SMGThe Scotts Miracle-Gro CompanyAugust 05, 2024Join
GRTSGritstone bio, Inc.August 06, 2024Join
RBLXRoblox CorporationAugust 12, 2024Join
TWOU2U, Inc.August 12, 2024Join
LWLamb Weston Holdings, Inc.August 12, 2024Join
TDCTeradata CorporationAugust 13, 2024Join
NKENIKE, Inc.August 19, 2024Join
PATHUiPath, Inc.August 19, 2024Join
FFFutureFuel Corp.August 23, 2024Join
TMToyota Motor CorporationAugust 23, 2024Join
SRGSeritage Growth PropertiesAugust 30, 2024Join
MDBMongoDB, Inc.September 09, 2024Join
WBAWalgreens Boots Alliance, Inc.September 10, 2024Join
CVSCVS Health CorporationSeptember 10, 2024Join